sarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.

Size: px
Start display at page:

Download "sarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ."

Transcription

1 1994, The British Journal of Radiology, 67, Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER, MD, FRCPATH department of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK, department of Histopathology, Brompton Hospital, Fulham Road, London SW3 6HP, UK and Departments of 3 Radiology and "Histopathology, Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK Abstract Metastases develop in 50-60% of patients with high grade soft tissue sarcomas despite primary treatment. Between 1970 and 1990, 189 patients with soft tissue sarcoma referred to the Royal Marsden Hospital Sarcoma Unit developed lung metastases as the sole first site of disseminated disease. 44 of these 189 cases have been treated by pulmonary metastasectomy. In an attempt to determine which patients benefit from this surgery the medical records, radiology and pathology of these cases have been reviewed. Both the overall 5 year survival (70% vs 19%) and the subsequent survival from the time lung metastases developed (52% vs 7.5%) of those selected for thoracotomy were better than in the 145 patients not undergoing surgery. On multivariate analysis, survival and control of lung disease following resection were not related to the number of metastases resected, completeness of excision, use of adjuvant chemotherapy or presence of bilateral disease. The most important factor was the use of lung resection itself as treatment, for which the risk of death was 0.2 compared with those not having metastasectomy. Age less than 40 years and primary tumour in a lower limb site were also factors associated with a reduced risk of death. Pulmonary metastasectomy should be considered in selected patients with soft tissue sarcoma after primary local cure. However, without collection of prospective data on all patients developing lung metastases or a randomized trial the true role of lung metastasectomy will never be clarified. Metastases develop in 50-60% of patients with high grade soft tissue sarcomas and without treatment are almost invariably fatal [1]. The lung predominates as the site of first metastasis. In 1964 Clagett demonstrated a 23% 5 year survival following resection of metastatic sarcoma [2]. Results similar to those seen in osteosarcoma have been reported by others [3-5]. Survival following pulmonary metastasectomy has been correlated in some series [4, 5] with the length of the disease free interval following treatment of the primary tumour. Patients with a disease free interval of less than 12 months appear to do particularly badly. Other workers have associated prognosis with tumour doubling time [7], number of metastases and resectability [6-8]. However, the results in the literature are not consistent [8] which makes it difficult to detail an appropriate treatment policy for patients developing lung metastases. The patterns of metastasis in a group of patients referred to the Royal Marsden Hospital Sarcoma Unit Received 24 May 1993 and in revised form 12 July 1993, accepted 26 July Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ. with soft tissue sarcoma were documented and a detailed study of those undergoing subsequent pulmonary metastasectomy was performed. To determine the value of this procedure, the survival of this selected group was compared with the survival of a cohort of patients not offered metastasectomy. Patients and Methods All patients 293 patients referred to the Royal Marsden between 1970 and 1990 with a diagnosis of soft tissue sarcoma have developed metastatic disease (other than lymph nodes). Of these, 189 had lung metastases as the first and only evidence of metastatic spread. Patients with lung metastases Lung metastases were usually diagnosed radiogically by chest radiography, linear tomography or computed tomography (CT). Since 1985, CT of the lungs has been carried out on referral. Clinical follow-up after treatment of the primary tumour was carried out at 2 monthly intervals for the first year, 3 monthly for the second, 6 monthly until the fifth, and yearly thereafter. Routine chest radiographs and chest CT were carried out for the first 5 years, with a plainfilmat each visit and chest CT 3 monthly for the first year, 4 monthly for the second, 6 monthly for the third and yearly thereafter. Vol. 67, No

2 M H Robinson, M Sheppard, E Moskovic and C Fisher Table I. Factors assessed by multivariate analysis for independent prognostic value for survival following development of lung metastasis Table II. Number of lung metastases found at resection Number of metastases Number of patients Age: 40-50, 50-60, and > 60 years Site: lower limb, upper limb, girdle, truncal, head and neck, retroperitoneal Histology Grade Size: < 5 cm, 5-10 cm, > 10 cm Depth: superficial vs deep History: < 1 year vs > 1 year Lung metastasis resection performed vs not Time to metastasis from diagnosis Unknown 22 6 The histopathology of the resected metastases, medical records, chest radiographs and CT scans of 44 patients subjected to pulmonary metastasectomy (since 1980) have been reviewed. Each patient had histologically confirmed pulmonary metastases. 28 men and 16 women (median age 32 years) have been studied. The majority of primaries in this group were in the extremity or girdle (35). Malignant fibrous histiocytoma (10), synovial sarcoma (8) and sarcoma of unspecified histology (6) were the commonest histological types. Tumours were categorized as high, intermediate or low grade. Most were high grade (37) with seven low grade and no intermediate grade tumours. The mean length of history prior to diagnosis of the primary was similar in those 44 patients undergoing metastasectomy compared with those 145 that did not (316 vs 322 days). Treatment policy for the management of lung metastases was not consistent prior to However, patients with solitary lung lesions or a long disease free interval with no evidence of recurrence at other sites were considered suitable for metastasectomy. In 1987 this treatment policy was formalized in that surgery was offered to patients with four or fewer lesions and a disease free interval of over 1 year. After confirmation that surgery was technically possible, these patients were first given two courses of chemotherapy with either adriamycin or ifosfamide to evaluate response. Surgery was then performed. Four further courses were given postoperatively to those in whom a partial response to chemotherapy was seen. Only 12 patients were entered into this protocol. The tumour doubling time of resected lung metastases was calculated for those patients for whom radiology was available for review. Actuarial curves for time to metastasis, survival and freedom from disease were determined by the method of Kaplan and Meier and compared using the logrank test [9, 10]. A Cox stepwise regression model using the Biomedical Statistics package (BMDP) was used to assess the individual impact of all potential prognostic factors on survival following diagnosis of lung metastasis [11]. Table I details the factors entered into the multivariate analysis. Results Time to metastasis Median time to lung metastasis from diagnosis was greater in those undergoing metastasectomy than those who did not (674 vs 391 days; p = 0.017). In those undergoing surgery 10 patients had recurred locally prior to developing lung metastases, three recurred at the same time and four afterwards. In only one case was there another site of active disease at the time of thoracotomy. This was a synchronous metastasis in the liver which was also treated surgically. The mean number of lung metastases detected radiologically prior to resection was two. 11 patients had metastases in both lungs. Pulmonary surgery Complete resection of known pulmonary lesions was achieved at thoracotomy in all but five patients. In four cases this was because of pleural disease. The majority of patients had a wedge resection of the metastases. Bilateral thoracotomy was performed via a median sternotomy in seven cases and by a two stage operation in two cases. The surgeon was unable to palpate the lesion in the second lung in one case (successfully treated with radiotherapy), and another patient died before the second operation. Pneumonectomy was required in two patients. The mean number of metastases found at surgery was two (range 1-15) (Table II), with 22 patients having only one. However, on nine occasions more lesions were present than were discovered pre-operatively and on three occasions fewer. Thefindingof more metastases at operation than had been diagnosed radiologically preoperatively occurred in only one patient with a solitary metastasis radiologically compared with 6/11 with bilateral disease. The size of the 126 lesions resected ranged from 2 to 85 mm. Six patients had documented surgical complications. Most were minor apart from one pulmonary embolus and one post-operative death related to tumour embolus into the middle cerebral artery. Tumour doubling time The doubling time of pulmonary metastases prior to resection was calculated from chest radiography or CT 130 The British Journal of Radiology, February 1994

3 Lung metastasectomy in sarcomas LUNG RESECTION NO RESECTION EOLLOW UP (days) Figure 1. Survival from diagnosis of primary tumour for patients developing lung metastasis as first sole site of metastasis according to whether they underwent metastasectomy. in 15 patients. This ranged from 35 to 2200 days (mean 350, median 225). Radiotherapy and chemotherapy 14 patients undergoing metastasectomy had received adjuvant chemotherapy; eight before thoracotomy, one after and five before and after the surgery. The majority of patients received single agents; six patients were given adriamycin and six ifosfamide. Other drugs used included methotrexate (two patients), cyclophosphamide (three), vincristine (three), carboplatin (one), VP16 (one) and vindesine (one). One patient received radiotherapy to the site of unresected disease in her other lung immediately after surgery. She was treated with a dose of 19.8 Gy given in 6.6 Gy fractions once a week over 3 weeks. 48 out of 145 patients not undergoing metastasectomy received palliative chemotherapy. Survival Survival of all patients. Median follow-up for survival from diagnosis of the primary lesion is 1433 days and, from the diagnosis of lung metastases, 297 days. Figures 1 and 2 compare the survival from diagnosis and the survival from the time of development of lung metastases, respectively, of the 44 patients in this series undergoing metastasectomy with that of 145 patients who did not. The survival of those selected for thoracotomy was better than that of those not undergoing surgery (p < ). A multivariate analysis was performed to assess the factors determining outcome following the development of lung metastasis for the 189 patients in this series. The factors entered into this analysis included site, histology, grade and time from diagnosis to the development of metastasis (Table I). The result is given in Table III. Only the use of lung metastasectomy and superficial primary tumour depth were significant independent factors for survival, both associated with a reduced risk of death. The metastasis free interval was not. Survival of those undergoing lung resection. Median survival following thoracotomy was not related to the length of the disease free period following treatment of the primary (Figure 3). Survival following resection was also not significantly Vol. 67, No

4 M H Robinson, M Sheppard, E Moskovic and C Fisher I I L LUNG RESECTION NO LUNG RESECTION TIME FROM LUNG METASTASIS Figure 2. Survival from development of lung metastasis as first sole site of metastasis according to whether patients underwent metastasectomy related to the number of metastases resected (Figure 4; p = 0.49) or to the use of adjuvant chemotherapy (p = 0.33). Patients with bilateral metastases and those with incomplete resection did not appear to do worse. Recurrence in lung 28 patients undergoing thoracotomy have subsequently developed further recurrent or metastatic tumour. 21 patients have developed further lung metastases; 18 in the lung alone, one in combination with local recurrence, one with liver and bone disease, and one who initially relapsed locally has subsequently also relapsed in the lung. Eight patients have received no further treatment following disease relapse. Three patients have undergone a second thoracotomy. Of these two have died, one of whom had a further relapse in the lung. Five patients have had further surgery for logical relapse. Four patients have received chemotherapy followed by radiotherapy for lung disease, two chemotherapy alone and two radiotherapy alone. One patient who developed a solitary brain metastasis has undergone local resection and whole brain radiotherapy. The use of adjuvant chemotherapy was not associated with a reduction in further lung relapse on univariate analysis (p = 0.87). Neither the presence of bilateral metastases nor incomplete surgical resection (0.89) significantly increased the likelihood of further relapse in the lung. There were too few patients in the metastasectomy Table III. Significant prognostic factors for survival following the development of lung metastasis Factor Hazard for Relative to Hazard ratio P Metastasectomy Depth primary Operation Superficial None Deep 0.2( ) 0.28 ( ) The British Journal of Radiology, February 1994

5 Lung metastasectomy in sarcomas <= 1 YEAR OVER 1 YEAR <= 2 YEARS OVER 2 YEARS TIME FROM SURGERY TIME FROM SURGERY Figure 3. Survival according to time to metastasis; < 1 year vs > 1 year and < 2 years vs > 2 years not significant group for a reliable Cox model to be calculated for either survival or lung recurrence. Discussion It has long been appreciated that many patients who die of lung metastases are otherwise disease free [12, 13]. The results in the literature suggest that the 5 year survival following lung metastasectomy for soft tissue sarcoma is better than that for resection of primary bronchogenic carcinoma. However, it is not clear which patients should be selected for this operation. Some authors believe that only patients with solitary lesions are suitable [14-16]. There is conflicting evidence for the importance of disease free interval in determining prognosis. Some authors have reported that disease free interval following primary treatment is an important prognostic factor and others that it is not [6, 17]. In this study no influence of disease free interval on survival was seen. A review of the practice at the Memorial Sloan Kettering Hospital suggested that results were best where complete resection of the lesions was achieved and were not influenced by either the number of metastases or the disease free interval [8]. A similar finding in osteosarcoma has been reported [18]. Pastorino reported 28 cases of soft tissue sarcoma lung metastases completely resected between 1970 and 1987 [19]. Their median interval to lung metastasis was 2 years compared with 13 months in this series, suggesting that there was some selection of cases considered for resection. Neither the number of metastases nor the disease free interval affected survival following resection in this group. Disease free survival following resection was 42% at 5 years. Another study reported the results of reoperation following second lung relapse; and suggested that the interval between first thoracotomy and relapse was the most important prognostic factor [20]. In general the results from most series are similar with 20-40% 5 year survival following this operation with a low operative mortality. However, the series are usually small and this treatment has not been offered as part of a randomized trial. The results seen in our study are similar to those seen elsewhere in the literature {e.g. see ref. 21). The problem remains as to how to improve Vol. 67, No

6 M H Robinson, M Sheppard, E Moskovic and C Fisher 1 - J I i <=2 LUNG METASTASES >2 LUNG METASTASES DAYS FROM SURGERY Figure 4. Survival following lung metastasectomy according to number of lesions resected. 460 further the outlook for these patients. There is little evidence in the literature that the use of adjuvant chemotherapy with current drugs is of value in increasing disease free survival in these patients. The evidence from trials of its use as part of the primary treatment have indicated that it is of no value in prolonging survival [22]. Unfortunately, despite careful patient selection, 80% of patients undergoing metastasectomy will die from their disease, predominantly with lung recurrence. It is clear that an effective adjuvant therapy is required to improve these results. This is as yet not available. It is likely that the routine use of CT results in earlier diagnosis of lung metastases. However, CT may remain equivocal for a period during which a watch policy is instituted to confirm the diagnosis. This may mean that any advantage of earlier diagnosis is lost. It is clear from the literature that resection of pulmonary metastases is worthwhile for a selected group of patients with metastatic soft tissue sarcoma [2-4, 8]. A longer initial disease free interval and fewer lung metastases present at resection may increase the likelihood that the patient will remain disease free. However, the true value of this procedure will only become clear if patients are entered into multicentre randomized trials designed to answer this question. An alternative would be to document prospectively the outcome for all patients with soft tissue sarcoma developing lung metastases as the sole site of recurrence. Acknowledgments Dr M H Robinson is a Senior Lecturer supported by the Yorkshire Cancer Research Campaign. References 1. POTTER, D A, KINSELLA, T, GLATSTEIN, E ET AL, High grade soft tissue sarcomas of the extremities, Cancer, 58, (1986). 2. CLAGETT, O T, ALLEN, T H, PAYNE, W P and WOOLNER, L B, The surgical treatment of pulmonary neoplasms: a 10-year experience. /. Thorac. Cardiovasc. Surg. 48, (1964). 3. FELDMAN, P S and KYRIAKOS, M, Pulmonary resection for metastatic sarcoma, J. Thorac. Cardiovasc. Surg. 64, (1972). 4. PUTNAM, J B, ROTH, J A, WESLEY, M N ET AL, Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas, J. Cardiovasc. Surg. 87, (1984). 5. VENN, G E, SARIN, S and GOLDSTRAW, P, Survival following pulmonary metastasectomy, Eur. J. Cardiothorac. Surg. 3, (1989). 134 The British Journal of Radiology, February 1994

7 Lung metastasectomy in sarcomas 6. JABLONS, D, STEINBERG, S M, ROTH, J ET AL, Metastasectomy for soft tissue sarcoma, J. Thorac. Cardiovasc. Surg. 97, (1989). 7. JOSEPH, W L, MORTON, D L and ADKINS, P C, Prognostic significance of tumour doubling time in evaluating operability of pulmonary metastatic disease, /. Thorac. Cardiovasc. Surg. 61, (1971). 8. MARTINI, N and McCORMACK, P M, Pulmonary resection in sarcoma metastases, Dev. Oncol. 55, (1988). 9. KAPLAN, E S and MEIER, P, Non-parametric estimation from incomplete observation, J. Am. Statist. Assoc. 53, (1958). 10. PETO, R, PIKE, M C, ARMITAGE, P ET AL, Design and analysis of randomised clinical trials requiring prolonged observation of each patient, 11 analyses and examples. 19 The log rank test, Br. J. Cancer, 35, 1-39 (1971). 11. COX, D R, Regression models and life-tables, /. R. Statist. Soc. 34, (1972). 12. FARRELL, J T, Pulmonary metastases: a pathologic, clinical, roentgenologic study based on 78 cases seen at necropsy, Radiology, 24, 444 (1935). 13. WILLIS, R A, The Spread of Tumours in the Human Body (Butterworth, London) (1952). 14. ALEXANDER, J and HAIGHT, C, Pulmonary resection for solitary metastatic sarcomas and carcinomas, Surg. Gynaecol. Obstet. 85, 129 (1947). 15. EHRENHAFT, J L, Pulmonary resections for metastatic lesions, Arch. Surg. 63, 326 (1951). 16. GLIEDMAN, M L, HOROWITZ, S and LEWIS, F J, Lung resection for metastatic cancer: 29 cases from the university of Minnesota and a collected review of 264 cases, Surgery, 42, 521 (1957). 17. MOUNTAIN, C F, McMURTREY, M J and HERMES, K E, Surgery for pulmonary metastasis: a 20 year experience, Ann. Thorac. Surg. 38, (1984). 18. GOORIN, A M, DELOREY, M J, LACK, E E ET AL, Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients, J. Clin. Oncol. 2, 425^31 (1984). 19. PASTORINO, U, VALENTE, M, GASPARINI, M ET AL, Lung resection for metastatic sarcomas: total survival from primary treatment, J. Surg. Oncol. 404, (1989). 20. POGREBNIAK, H W, ROTH, J A, STEINBERG, SMet al, Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma, Ann. Thorac. Surg. 52, (1991). 21. FLY, M W, WOLTERING, G and ROSENBERG, S A, Aggressive pulmonary resection for metastatic osteogenic and soft tissue sarcomas, Ann. Thorac. Surg. 37, (1987). 22. BRAMWELL, V H C, ROUESSE, J, SANTORO, A, BUESA, J ET AL, European experience of adjuvant chemotherapy for soft tissue sarcomas. Preliminary report of randomised trial of cyclophosphamide, vincristine, doxorubicin and dacarbazine. Cancer Treat. Symp. 3, (1985). Vol. 67, No

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated

More information

Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy

Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication

More information

Results of thoracotomy in osteogenic sarcoma

Results of thoracotomy in osteogenic sarcoma Thorax 1991;46:727-731 Bone Tumour Treatment Service, Royal Orthopaedic Hospital, Birmingham B31 2AP S R Carter R J Grimer R S Sneath Thoracic Surgery Unit, East Birmingham Hospital, Birmingham B9 SST

More information

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Surgical Approaches to Pulmonary Metastases

Surgical Approaches to Pulmonary Metastases Surgical Approaches to Pulmonary Metastases Raja M Flores MD Professor and Chief Thoracic Surgery Mount Sinai School of Medicine New York, New York History of Lung Metastasectomy 1882 Weinlechner +CW 1926

More information

S from connective tissue and account for approximately

S from connective tissue and account for approximately Reoperative Pulmonary Resection in Patients With Metastatic Soft Tissue Sarcoma Helen W. Pogrebniak, MD, Jack A. Roth, MD, Seth M. Steinberg, PhD, Steven A. Rosenberg, MD, PhD, and Harvey I. Pass, MD Thoracic

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

All India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology

All India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal

More information

VATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS

VATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS VATS Metastasectomy Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute Disclosures Speaking & Education:

More information

Carcinoma of the Lung

Carcinoma of the Lung THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and

More information

CASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003

CASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003 CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli

More information

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

In the past, pulmonary metastases (PM) were considered

In the past, pulmonary metastases (PM) were considered Original Article The Role of Extended Pulmonary Metastasectomy Monica Casiraghi, MD,* Patrick Maisonneuve, Eng, Daniela Brambilla, Msc,* Francesco Petrella, MD,* Piergiorgio Solli, MD,* Juliana Guarize,

More information

ORIGINAL ARTICLE. Benefit of Surgical Treatment of Lung Metastasis in Soft Tissue Sarcoma

ORIGINAL ARTICLE. Benefit of Surgical Treatment of Lung Metastasis in Soft Tissue Sarcoma ORIGINAL ARTICLE Benefit of Surgical Treatment of Lung Metastasis in Soft Tissue Sarcoma Alexander Rehders, MD; Stefan B. Hosch, MD; Peter Scheunemann, MD; Nikolas H. Stoecklein, MD; Wolfram T. Knoefel,

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;

More information

Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy

Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

Pulmonary Resection for Metastases from Colorectal Cancer

Pulmonary Resection for Metastases from Colorectal Cancer ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,

More information

T tases in patients with soft-tissue sarcomas is well

T tases in patients with soft-tissue sarcomas is well Response to Chemotherapy Does Not Predict Survival After Resection of Sarcomatous Pulmonary etastases Louis A. Lanza, D, Joe B. Putnam, Jr, D, Robert S. Benjamin, D, and Jack A. Roth, D Departments of

More information

Treatment of oligometastatic NSCLC

Treatment of oligometastatic NSCLC Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Tumour size as a prognostic factor after resection of lung carcinoma

Tumour size as a prognostic factor after resection of lung carcinoma Tumour size as a prognostic factor after resection of lung carcinoma A. S. SOORAE AND R. ABBEY SMITH Thorax, 1977, 32, 19-25 From the Cardio-Thoracic Unit, Walsgrave Hospital, Clifford Bridge Road, Coventry

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

ARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW

ARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter

More information

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals 6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide, Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the

More information

Fifteen-year follow-up of all patients in a study of

Fifteen-year follow-up of all patients in a study of Br. J. Cancer (1985), 52, 867-873 Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma D.J. Girling, H. Stott, R.J. Stephens & W. Fox Medical Research

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

Key words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery

Key words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases* Pierre Bonnette, MD; Philippe Puyo, MD; Christophe Gabriel, MD; Roger Giudicelli, MD; Jean-François Regnard, MD; Marc

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

Pulmonary resection for metastatic colorectal carcinoma was first performed

Pulmonary resection for metastatic colorectal carcinoma was first performed General Thoracic Surgery Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment Yukihito Saito, MD, a Hideyasu Omiya, MD, a Keijiro Kohno, MD, b Takanobu Kobayashi,

More information

Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn

Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn Isadore Mandelbaum, M.D., Stephen D. Williams, M.D., and Lawrence H. Einhorn, M.D. ABSTRACT During the past

More information

Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk

Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk 843 Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk Tadashi Hasegawa, M.D. 1 Seiichiro Yamamoto, Ph.D. 2

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

Excision of pulmonary metastases of osteogenic sarcoma of the limbs q

Excision of pulmonary metastases of osteogenic sarcoma of the limbs q European Journal of Cardio-thoracic Surgery 15 (1999) 592±596 Excision of pulmonary metastases of osteogenic sarcoma of the limbs q Manuel Antunes*, JoaÄo Bernardo, Maria Salete, David Prieto, Luis EugeÂnio,

More information

Update on Sarcomas of the Head and Neck. Kevin Harrington

Update on Sarcomas of the Head and Neck. Kevin Harrington Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced

More information

Introduction ORIGINAL RESEARCH

Introduction ORIGINAL RESEARCH Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis

More information

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation

More information

The lungs are the second most frequent site for metastases

The lungs are the second most frequent site for metastases Prognostic Factors for Survival After Pulmonary Resection of Metastatic Renal Cell Carcinoma Joachim Pfannschmidt, MD, Hans Hoffmann, MD, PhD, Thomas Muley, PhD, Sabine Krysa, MD, Christine Trainer, MD,

More information

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo

More information

Age group No. of patients >60 15 Total 108

Age group No. of patients >60 15 Total 108 88 Original Article Soft Tissue Sarcoma in Uganda. A.M. Gakwaya 1, J. Jombwe 2, 1 Senior Consultant Surgeon, 2 Senior registrar, Dept. Of Surgery Mulago Hospital Complex, Kampala, Uganda Correspondence

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Germ cell tumors (GCT) are uncommon neoplasms

Germ cell tumors (GCT) are uncommon neoplasms ORIGINAL ARTICLES: GENERAL THORACIC Pulmonary Metastasectomy for Testicular Germ Cell Tumors: A 28-Year Experience David Liu, MD, Amir Abolhoda, MD, Michael E. Burt, MD, PhD, Nael Martini, MD, Manjit S.

More information

Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients

Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients INGO ALLDINGER 1,2, QIN YANG 3, CHRISTIAN PILARSKY 1, HANS-DETLEV SAEGER 1, WOLFRAM T. KNOEFEL

More information

Pan Arab Journal of Oncology

Pan Arab Journal of Oncology Pan Arab Journal of Oncology Original Article Retrospective Analysis of Clinicopathologic and Management Aspects of Soft Tissue Sarcoma Tarek Hussein Kamel, Azza Mohamed Adel, Reham Mohamed Faheim, Rana

More information

Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer

Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic

More information

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,

More information

Multidisciplinary management of retroperitoneal sarcomas

Multidisciplinary management of retroperitoneal sarcomas Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake

More information

Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin

Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin Annals of Oncology 21: 1915 1921, 2010 doi:10.1093/annonc/mdq039 Published online 18 February 2010 Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin

More information

Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience

Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience Clinton D. Kemp, MD,* R. Taylor Ripley, MD,* Aarti Mathur, MD, Seth M. Steinberg, PhD, Dao M. Nguyen,

More information

Doppler ultrasound of the abdomen and pelvis, and color Doppler

Doppler ultrasound of the abdomen and pelvis, and color Doppler - - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors

More information

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,

More information

UPDATE ON RADIOTHERAPY

UPDATE ON RADIOTHERAPY 1 Miriam Kleiter UPDATE ON RADIOTHERAPY Department for Companion Animals and Horses, Plattform Radiooncology and Nuclear Medicine, University of Veterinary Medicine Vienna Introduction Radiotherapy has

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients

Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

We have studied 560 patients with osteosarcoma of a

We have studied 560 patients with osteosarcoma of a Osteosarcoma of the limb AMPUTATION OR LIMB SALVAGE IN PATIENTS TREATED BY NEOADJUVANT CHEMOTHERAPY G. Bacci, S. Ferrari, S. Lari, M. Mercuri, D. Donati, A. Longhi, C. Forni, F. Bertoni, M. Versari, E.

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

Surgical resection of pulmonary metastases is an established

Surgical resection of pulmonary metastases is an established Long-Term Results After Pulmonary Resection of Renal Cell Carcinoma Metastases Stefan Piltz, MD, Georgios Meimarakis, MD, Matthias W. Wichmann, MD, Rudolf Hatz, MD, Friedrich Wilhelm Schildberg, MD, and

More information

Prognostic Factors and Survival after Pulmonary Resection ofmetastaticrenalcellcarcinoma

Prognostic Factors and Survival after Pulmonary Resection ofmetastaticrenalcellcarcinoma European Urology European Urology 48 (2005) 77 82 Kidney Cancer Prognostic Factors and Survival after Pulmonary Resection ofmetastaticrenalcellcarcinoma Hans-Stefan Hofmann*, Heinz Neef, Katharina Krohe,

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater

More information

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to

More information

Case report Osteosarcoma of long bone metastatic to the pancreas-an unusual site of

Case report Osteosarcoma of long bone metastatic to the pancreas-an unusual site of Osteosarcoma of long bone metastatic to the pancreas-an unusual site of Dr. Santosh Kumar Singh 1, Col (Dr.) Narayanan Kannan 2, Brig (Dr) Rajnish Talwar 3, ABSTRACT Col (Dr) Arvind Kumar Tyagi 4, Dr Adarsh

More information

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018 30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Surgical Treatment for Pulmonary Me. Tsunehisa; Kugimiya, Toshiyasu. Citation Acta medica Nagasakiensia. 1983, 28

Surgical Treatment for Pulmonary Me. Tsunehisa; Kugimiya, Toshiyasu. Citation Acta medica Nagasakiensia. 1983, 28 NAOSITE: Nagasaki University's Ac Title Author(s) Surgical Treatment for Pulmonary Me Ayabe, Hiroyoshi; Tomita, Masao; Na Katsunobu; Nakao, Susumu; Eguchi, M Tsunehisa; Kugimiya, Toshiyasu Citation Acta

More information

Xiang Hu*, Liang Cao*, Yi Yu. Introduction

Xiang Hu*, Liang Cao*, Yi Yu. Introduction Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang

More information

The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma

The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,

More information

Evaluation of prognostic scoring systems for bone metastases using single center data

Evaluation of prognostic scoring systems for bone metastases using single center data MOLECULAR AND CLINICAL ONCOLOGY 3: 1361-1370, 2015 Evaluation of prognostic scoring systems for bone metastases using single center data HIROFUMI SHIMADA 1, TAKAO SETOGUCHI 2, SHUNSUKE NAKAMURA 1, MASAHIRO

More information

EVIDENCE BASED MANAGEMENT FOR SOFT TISSUE SARCOMA

EVIDENCE BASED MANAGEMENT FOR SOFT TISSUE SARCOMA EVIDENCE BASED MANAGEMENT FOR SOFT TISSUE SARCOMA A Documentation of exact extent of primary tumor Clinical examination, X-ray, MRI (MRI has become the premier imaging modality for the evaluation of musculoskeletal

More information

24 Ann Thorac Surg 46:24-28, July Copyright by The Society of Thoracic Surgeons

24 Ann Thorac Surg 46:24-28, July Copyright by The Society of Thoracic Surgeons Surgical Management of Lung Cancer with Solitary Cerebral Metastasis John R. Hankins, M.D., John E. Miller, M.D., Michael Salcman, M.D., Frank Ferraro, M.D., David C. Green, M.D., Safuh Attar, M.D., and

More information

Colon cancer is still one of the leading causes of

Colon cancer is still one of the leading causes of Long-Term Survival After Repeated Resection of Pulmonary Metastases From Colorectal Cancer Stefan Welter, MD, Jan Jacobs, MD, Thomas Krbek, MD, Bettina Krebs, MD, and Georgios Stamatis, MD Department of

More information

Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma

Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma of the Lung Scott L. Faulkner, M.D., R. Benton Adkins, Jr., M.D., and Vernon H. Reynolds, M.D. ABSTRACT Ten patients with inoperable or recurrent

More information

Lung cancer: the importance of seeing a respiratory physician

Lung cancer: the importance of seeing a respiratory physician Eur Respir J 2003; 21: 606 610 DOI: 10.1183/09031936.03.00060803 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Lung cancer: the importance

More information

ORIGINAL ARTICLE. Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors

ORIGINAL ARTICLE. Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors Predictors of Survival? Robert C. G. Martin II, MD; Murray F. Brennan, MD ORIGINAL ARTICLE Background: Ewing sarcoma (ES) is the second

More information

Adam J. Hansen, MD UHC Thoracic Surgery

Adam J. Hansen, MD UHC Thoracic Surgery Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered

More information

Management of single brain metastasis: a practice guideline

Management of single brain metastasis: a practice guideline PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA

More information

Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer

Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François

More information

Lung cancer is one of the most common and most. Delays in the Diagnosis and Treatment of Lung Cancer*

Lung cancer is one of the most common and most. Delays in the Diagnosis and Treatment of Lung Cancer* Delays in the Diagnosis and Treatment of Lung Cancer* Eija-Riitta Salomaa, MD, PhD; Susanna Sällinen, BM; Heikki Hiekkanen, MSc; and Kari Liippo, MD, PhD Study objectives: This study was undertaken to

More information

In 2004, approximately 55,100 people in the United States were diagnosed with

In 2004, approximately 55,100 people in the United States were diagnosed with Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma Rebecca P. Petersen, MD, MSc, a Steven I. Hanish, MD, a John C. Haney, MD, a Charles C.

More information

The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer

The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,

More information